Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avocado-soybean unsaponifiables is a natural vegetable extract composed of the unsaponifiable fractions of avocado and soybean oils, typically in a 1:2 ratio. It is used primarily as a symptomatic slow-acting drug in osteoarthritis (SYSADOA) for hip and knee osteoarthritis, but also considered for scleroderma, menopause-related symptoms, and other conditions[1][3][5][8]. ASU is chondroprotective, anti-inflammatory, anabolic, and anticatabolic—stimulating collagen and proteoglycan synthesis, decreasing matrix metalloproteinase activity, reducing pro-inflammatory cytokine production (such as IL-1, IL-6, TNF-alpha), and blocking COX-2 expression and PGE2 secretion. Its principal active components include phytosterols (beta-sitosterol, campesterol, stigmasterol), isoflavones, tocopherols, and squalene[1][3]. Its mechanism of action is not fully understood but is thought to act by modulating connective tissue metabolism and reducing inflammatory mediators in articular joints[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avocado-soybean unsaponifiables.